Welcome to Insider Healthcare. I’m Lydia Ramsey Pflanzer, and today in healthcare news:
- See the pitch deck Swift Medical used to raise $35 million for its approach to wound care;
- We spoke to fully vaccinated people who got COVID-19 about what it was like to have a breakthrough infection;
- At a Stat event, Eli Lilly’s CEO shared the company’s plans to treat obesity with an experimental diabetes medication.
- Swift Medical has an app that uses AI and 3D imaging to remotely manage wound care.
- The app was primarily designed for nurses and clinicians caring for chronic-wound patients.
- The COVID-19 vaccines are extremely effective, but a rare few vaccinated people have gotten sick.
- “Breakthrough” infections are typically mild and might be less contagious than regular cases.
- To completely prevent infections, more of the population needs to get vaccinated.
- Eli Lilly’s CEO thinks tirzepatide, an experimental diabetes treatment, could also treat obesity.
- In a clinical trial, people with diabetes who received tirzepatide lost on average 25 pounds.
- There are few effective weight-loss drugs available.
More stories we’re reading:
- How 4 of the US’s most vaccinated counties got shots to more than 70% of their residents (Insider)
- Deaths from drug overdoses jumped by nearly 30% in 2020 to more than 93,000 (Washington Post)
- South Korea bans fast-paced music in gyms and limits treadmill speeds to a walk as COVID-19 cases soar (Insider)
- Stat grilled acting FDA Commissioner Janet Woodcock about the agency’s controversial Alzheimer’s approval (Stat News)